CollPlant Biotechnologies (CLGN)
(Delayed Data from NSDQ)
$2.77 USD
+0.52 (23.11%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $2.72 -0.05 (-1.81%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CLGN 2.77 +0.52(23.11%)
Will CLGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CLGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLGN
CollPlant (CLGN), Stratasys Initiate Study for Breast Implants
Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains?
CLGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CLGN
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS | CLGN Stock News
CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial ...
CLGN: Shareholder Sales Won't Benefit Company Directly | CLGN Stock News
CollPlant files to sell 1.27M ordinary shares for holders
CollPlant files to sell 1.27M ordinary shares for holders